

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 072 251
A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82304224.7

(51) Int. Cl.²: A 61 L 15/06

(22) Date of filing: 10.08.82

(30) Priority: 10.08.81 US 291611

(71) Applicant: LecTec Corporation, 10215 Crosstown Circle, Eden Prairie Minnesota 55344 (US)

(43) Date of publication of application: 16.02.83
Bulletin 83/7


(72) Inventor: Hymes, Alan C., 3828 Wilmott Road, Hopkins Minnesota 55343 (US)
Inventor: Ong, Lincoln T., 5940 Fairwood Drive, Minnetonka Minnesota 55343 (US)
Inventor: Persons, Garry R., 5505 Highland Road, Edina Minnesota 55435 (US)

(84) Designated Contracting States: DE FR GB

(74) Representative: Dayneswood, Trevor et al, ABEL & IMRAY Northumberland House 303-306 High Holborn, London, WC1V 7LH (GB)

(84) Improved bandage containing a medicament.

(57) A flexible, liquid-absorbent, adhesive bandage includes a backing element and a substrate attached to the backing element. The substrate comprises a homogeneous, hydrophilic, stable matrix including a solid phase formed of a synthetic polymer and/or a long chain polysaccharide, or a combination thereof. The liquid phase of the matrix consists of a hydric alcohol, carbohydrates and/or proteins in an aqueous solution, and/or a combination thereof. The matrix contains a medicament therein for release to the affected areas.



EP 0 072 251 A2

0072251

IMPROVED BANDAGE CONTAINING A MEDICAMENT

BACKGROUND OF THE INVENTION

This invention relates to an improved bandage which contains a medicament that is topically released into the skin. The application is a continuation in part application of my co-pending application, Serial No. 173,001, filed on July 28, 1980, and entitled "Sterile Improved Bandage Containing a Medicament".

Attempts have been made to develop bandages which are self-adhesive, absorbent, and sterile. For example, U.S. Patent No. 3,339,546 discloses a self-adhesive bandage which is adapted to adhere to moist surfaces such as the moist mucosa of the oral cavity. However, one of the essential materials of this self-adhesive bandage is an adhesive gum, preferably polyisobutylene, which is hydrophobic. Similarly, U.S. Patent Nos. 3,598, 122 and 3,598,123 disclose bandages which contain drugs that are continually released from an adhesive layer. These bandages are formed of layered materials which have drugs encapsulated in the adhesive layer. Even though the bandage disclosed in there prior art patents are said to be self-adhesive and are satisfactory vehicles for drugs, specific process steps are required for encapsulating or stratifying the drugs.

SUMMARY OF THE INVENTION

Therefore, it is a general object of this invention to provide a self-adhesive, novel bandage in which a medicament is molecularly dispensed for release to the affected area. The bandage is comprised of a flexible backing element and a self-adhesive substrate which becomes increasingly

BAD ORIGINAL

0072251

tacky in the presence of moisture and which absorbs liquid and releases the medicament to the affected area while remaining dimensionally stable.

These and other objects and advantages of this invention will more fully appear from the following description made in connection with the accompanying drawings, wherein like reference characters refer to the same or similar parts throughout the several views.

FIGURES OF THE DRAWINGS

Fig. 1 is a perspective view illustrating the novel bandage applied to the arm of a patient.

Fig. 2 is a perspective view of a bandage illustrated in Fig. 1.

Fig. 3 is a perspective view of a bandage used as a surgical dressing.

Fig. 4 is a cross-sectional view taken approximately along line 4-4 of Fig. 2 and looking in the direction of the arrows.

Fig. 5 is a modified form of the bandage.

DESCRIPTION OF THE PREFERRED EMBODIMENT

The bandage of the present invention has adhesive properties for maintaining contact with the skin, as well as possessing a certain amount of elasticity for movement with the skin. The bandage is intended to be easily handled and is non-irritating to the patient.

Referring now to the drawings, it will be seen that the bandage of the present invention is there shown. The bandage, designated generally by the reference numeral 10, includes a backing member 11 and a self-adhesive substrate 12



0072251

0072251

which is secured to one end surface of the backing. The backing element 11 and the substrate 12 are both illustrated as rectangular sheets of material of uniform thickness. It is pointed out that the bandage 10 is intended to be regular in shape but may have any other configuration although the rectangular shape is preferred. In use, the bandage is applied with the substrate 12 in direct contact with the skin to cover a non-surgical wound, a surgical wound, or burned tissue. In Fig. 3, the embodiment illustrated therein is a surgical dressing and will be applied to the patient to cover a surgical wound.

Referring now to Fig. 5, it will be seen that a different embodiment of the bandage, designated generally by the reference numeral 10a, is there shown. The bandage includes a pressure-sensitive adhesive element 11a which serves as the backing element and also serves as the means for securing the bandage to the surface of the skin. The pressure-sensitive adhesive element 11a may be formed of any of the materials used in commercially available adhesive elements such as a foam-tape adhesive element. It will be appreciated that most of the commercially available adhesive elements maintain an excellent bond with the skin and are not irritable with respect to the skin.

Primary to the unique structure of the bandage is the hydrophilic adhesive properties of the substrate which enhance the adhesion thereof to the skin. The substrate not only absorbs moisture, making it ideal for use as a surgical dressing, but the substrate becomes tackier as it absorbs moisture.

The substrate 12 may be formed from naturally occurring materials such as gum karaya, guar gum, gum acacia,

0072251

locust bean gum, and other polysaccharides. The substrate may also be formed from synthetic polymers such as polyacrylamide and its congeners, such as methylene-Bis-acrylamide, polyacrylic acid molecular weights 250,000, 450,000, 1,000,000, and 4,000,000, and polyacrylamide sold under such trademarks as Reten by Hercules Company. When monomers such as acrylic acid or acrylamide are polymerized, it is necessary to use activators. Activators, which are used during polymerization, may include ferrous sulfate, sodium metabisulfite, potassium persulfate, as set forth in my co-pending application, Serial No. 58,684. The disclosure of my co-pending application, Serial No. 58,684, is incorporated by reference herein.

The synthetic polymers and/or natural gums and other polysaccharides constitute the solid phase of the matrix. The liquid phase of the matrix preferably consists of hydric alcohols such as glycerol or propylene glycol. Solutions or emulsions of saccharides and/or polysaccharides and/or proteins may be used in forming the matrix. Alternatively, a combination of a solution or emulsion of polysaccharides, saccharides, or proteins may be used in the liquid phase of the matrix.

The substrate 11 which is a stable matrix includes a solid phase comprising a synthetic polymer mixture, a karaya matrix, or a matrix of karaya and synthetic polymer. The solids of the matrix comprise 15% to 50% by weight of the matrix 11. The substrate may be sterilized. If the substrate is sterilized, the combination of the mixture is subjected to irradiation (usually gamma rays) of 2.5 mega rads for sterilization. Heretofore, this magnitude of irradiation to mixtures of polysaccharides, such as karaya with a hydric alcohol, preferably glycerol, would cause the matrix to lose dimensional stability with only slight pressure and/or water absorption.



0072251

This causes the matrix to become so tacky that it is not manageable as a surgical bandage. Further, if this irradiated karaya is used as a sterile pad to seal drainage as noted in the Hollister Patent No. 3,640,741, it may readily break down to a gelatinous substance which may run and break the seal.

The liquid phase of the matrix, such as hydric alcohol, comprises 30% to 70% by weight of the matrix.

The bandage also includes a suitable backing member which may include cotton fabric, woven or standard paper, synthetic fabrics, and/or plastics. Suitable synthetic fabrics may include nylon or polyester while a suitable plastic backing may include mylar or saran. When the bandage 10 is used as a surgical dressing, the backing element comprises a pervious material such as cotton fabric to permit diffusion of the absorbed liquid into the air.

The substrate 12 also contains a medicinal substance for release to the surface to which the bandage is applied. The medicinal substance is molecularly dispersed in the matrix rather than being encapsulated as in the prior art. The medicinal substance may include an antibacterial, antiseptic, or antifungal agents such as boric acid, bacitracin, acriflavin, formaldehyde, gential violet, mercuric sulfide, mercurochrome, neomycin, and iodine. Nitroglycerine may be used as a coronary.vaso dilater agent and hydrocortisone may be used as an anti-inflammatory agent. Suitable antipruritic agents include benzoin, calamine, camphor, menthol, phenol, and sulfur. The substrate may also include fragrances such as cinnamon oil, fir needle oil, lemon oil, peppermint oil, and spearmint. Suitable healing agents include allantoin, Peruvian balsam, Vitamin A, and Vitamin E. Hormonal agents may include

0072251

estrogen, progesterone, and testosterone. Protective agents may include benzoin, charcoal, talc, and zinc oxide. Salicylic acid is a suitable keratolytic agent and methyl salicylate is a suitable rubefacient. An exemplary antihistamine is chlorpheniramine.

The bandage also includes a suitable backing member which may include cotton fabric, woven or standard paper, synthetic fabrics, and plastics. Suitable synthetic fabric may include nylon or polyester while a suitable plastic backing may include mylar or saran.

When karaya or other natural gums are used in forming the matrix, it is necessary to use polyacrylic acid and/or polyacrylamide to protect or compensate degradation of karaya during irradiation, if the matrix is to be sterilized. However, a predetermined concentration of salts, such as aluminum sulfate or sodium chloride, may be used in the matrix with karaya in some instances in lieu of polyacrylamide and/or polyacrylic acid. For example, concentrations of approximately 6% sodium chloride or aluminum sulfate may be used with karaya in forming the solid phase of the matrix.

It has been found that vinyl acetate dioctyl maleate copolymer may also be advantageously used in forming the solid phase of the matrix. Vinyl acetate dioctyl maleate copolymer (sold under the trademark "Flexbond 150" by Air Products and Chemicals, Inc., and sold under the trademark "Bostik 8761" by the Bostik Company, Inc.) will intensify the tackiness of the bandage.

Another important gum material which may be used in forming the matrix is a starch graft copolymer sold under the trade name SGP 502S Absorbent Polymer by the Henkel Corporation, St. Paul, Minnesota. The starch graft copolymer product is

100-11-00

0072251

derived from corn starch and acrylonitrile and is a graft terpolymer of starch, acrylamide and sodium acrylate. The technical name for this starch graft copolymer product is starch-g-poly (acrylamide-co-sodium acrylate). The starch-g-poly material may be used alone to form the substrate or it may be used in combination with a synthetic gum such as acrylamide or a natural gum such as karaya. The starch-g-poly material is very effective as the skin contacting substrate since it does maintain its structural integrity and is non-toxic.

0072251

Example 1

| | <u>Nominal Amounts of Ingredients</u> | <u>Range of Ingredients</u> |
|-----------------|---|---------------------------------|
| Polyacrylamide | 5% | 1-50% |
| Karaya | 38% | 5-45% |
| Glycerol | 55% | 30-70% |
| Povidone-Iodine | 2% | 0.1-10% |

Example 2

| | | |
|------------------|-----|---------|
| Polyacrylic acid | 10% | 2-40% |
| Polyacrylamide | 10% | 2-40% |
| Karaya | 18% | 5-45% |
| Glycerol | 60% | 30-70% |
| Povidone-Iodine | 2% | 0.1-10% |

Example 3

| | | |
|------------------|-----|---------|
| Polyacrylamide | 15% | 2-40% |
| Polyacrylic acid | 15% | 2-40% |
| Glycerol | 68% | 30-70% |
| Povidone-Iodine | 2% | 0.1-10% |

Example 4

| | | |
|-------------------|-----|---------|
| Polyacrylamide | 30% | 2-40% |
| Glycerol | 62% | 50-70% |
| Methyl salicylate | 8% | 0.1-15% |

Example 5

| | | |
|-------------------------------|-------|---------|
| Polyacrylamide | 21.5% | 2-40% |
| Polyacrylic acid | 12.5% | 2-40% |
| Glycerol | 42% | 30-70% |
| Vinyl acetate-diethyl maleate | 16% | 10-20% |
| Methyl salicylate | 8% | 0.1-15% |

Example 6

| | | |
|-------------------|-----|---------|
| Polyacrylamide | 32% | 2-40% |
| Glycerol | 55% | 30-70% |
| Water | 6% | 1-10% |
| Methyl salicylate | 8% | 0.1-15% |

Example 7

| | | |
|----------------------------------|-----|---------|
| Povidone-Iodine | 2% | 0.1-10% |
| Hydroxy-propylcellulose (Klucel) | 6% | 0.1-10% |
| Glycerin | 56% | 30-70% |
| Water | 6% | 0.1-10% |
| Polyacrylamide (Reten 421) | 30% | 2-40% |



0072251

Example 8

| | <u>Nominal Amounts of Ingredients</u> | <u>Range of Ingredients</u> |
|----------------------------|---|---------------------------------|
| Povidone-Iodine | 10% | 0.1-15% |
| Reten 421 (polyacrylamide) | 5% | 2-40% |
| Karaya | 35% | 5-45% |
| Glycerol | 50% | 30-70% |

Example 9

| | | |
|-----------------|-----|---------|
| Povidone-Iodine | 2% | 0.1-10% |
| Karaya | 42% | 5-45% |
| Glycerol | 55% | 30-70% |

Example 10

| | | |
|------------------------|-----|---------|
| Camphor | 2% | 0.1-5% |
| Methylenebisacrylamide | 3% | 0.1-10% |
| Acrylic acid | 8% | 0.1-10% |
| Glycerol | 86% | 45-90% |
| Activators* | 1% | 0.1-2% |

*Potassium persulfate 0.6%
Sodium metabisulfite 0.2%
Ferrous sulfate 0.1%

Example 11

| | | |
|----------|-----|--------|
| Camphor | 2% | 0.1-5% |
| Glycerol | 5% | 30-70% |
| Karaya | 43% | 5-45% |

Example 12

| | | |
|-------------------------|-----|---------|
| Methyl salicylate | 2% | 0.1-10% |
| Methylene bisacrylamide | 5% | 0.1-10% |
| Acrylic Acid | 8% | 0.1-10% |
| Glycerol | 84% | 30-70% |
| Activators | 1% | 0.1-2% |

Example 13

| | | |
|------------------------|-----|---------|
| Methyl salicylate | 8% | 0.1-15% |
| Acrylic acid | 2% | 0.1-10% |
| Methylenebisacrylamide | 1% | 0.1-10% |
| Glycerol | 48% | 30-70% |
| Karaya | 40% | 5-45% |
| Activators | 1% | 0.1-2% |

0072251

Example 14

| | <u>Nominal Amounts Of Ingredients</u> | <u>Range of Ingredients</u> |
|-------------------|---|---------------------------------|
| Methyl salicylate | 8% | 0.1-15% |
| Karaya | 45% | 5-45% |
| Glycerol | 47% | 30-70% |

0

Example 15

| | | |
|--|-----|---------|
| Vinyl acetate dioctyl maleate copolymer | 62% | 50-75% |
| Vinyl acetate ethylene | 29% | 25-50% |
| NaCl | 1% | 1-5% |
| Methyl salicylate | 8% | 0.1-15% |

Example 16

| | | |
|----------------------------------|-----|---------|
| Vinyl acetate dioctyl maleate | 84% | 80-98% |
| Karaya | 12% | 5-45% |
| NaCl | 2% | 0.5-5% |
| Povidone-Iodine | 2% | 0.1-10% |

Example 17

| | | |
|----------------|-----|---------|
| Starch-g-poly | 30% | 15-50% |
| Glycerol | 62% | 30-70% |
| Nitroglycerine | 8% | 0.1-15% |

Example 18

| | | |
|----------------|-----|---------|
| Starch-g-poly | 25% | 1-30% |
| Glycerol | 55% | 30-70% |
| Karaya | 12% | 5-45% |
| Nitroglycerine | 8% | 0.1-15% |

0072251

WHAT IS CLAIMED IS:

1. A flexible, liquid-absorbent, adhesive bandage to be applied to a patient, comprising:

a flexible backing element selected from the group comprised of cotton, paper, synthetic fabric, and plastic,

a substrate attached to said backing element comprising a homogeneous, hydrophilic, stable matrix being sufficiently pliant to conform to the shape of the body contours, said matrix including a solid phase comprising about 15% to 50% of the total weight of the matrix and formed from a hydrophilic high-molecular polysaccharide and/or synthetic gum selected from the group comprising polyacrylic acid, polyacrylamide, and their congeners, vinyl acetate ethylene copolymer, vinyl acetate dioctyl copolymer, natural gums, and starch-g-poly, and a liquid phase consisting of a solution or emulsion selected from the group comprising carbohydrate, protein, and hydric alcohol, and comprising from 30% to 70% by weight of the matrix, said matrix containing a medicament selected from the group including vaso dilators, an antibacterial agent, antiseptic agent, antifungal agent, antihistamine agent, anti-inflammatory agent, antipruritic agent, hormonal agent, keratolytic agent, skin protective agent, and a rubefacient agent, said bandage having an adhesive surface for contact with and adhesion to a patient's skin;

2. The bandage as defined in claim 1 wherein said liquid phase comprises a solution of a polysaccharide;

3. The bandage as defined in claim 1 wherein said liquid phase comprises a hydric alcohol such as glycerol;

4. The bandage as defined in claim 1 wherein the solid phase of matrix includes a natural gum selected from the group comprising gum karaya, gum acacia, locust bean gum, and guar gum;

5. The bandage as defined in claim 4 wherein said liquid phase comprises glycerol;

6. The bandage as defined in claim 4 wherein said matrix is comprised of 5% to 45% by weight of gum karaya, 2% to 40% by weight of polyacrylamide, and 30% to 70% by weight of glycerol;

7. The bandage as defined in claim 1 wherein said matrix is comprised of 10% to 50% by weight of polyacrylamide and 30% to 70% by weight of glycerol;

8. The bandage as defined in claim 1 wherein said matrix is formed of 2% to 40% by weight of polyacrylamide and 2% to 40% by weight of polyacrylic acid, and 30% to 70% by weight of glycerol;

9. The bandage as defined in claim 1 wherein said matrix is formed of 2% to 50% by weight of polyacrylic acid and 30% to 70% by weight of glycerol;

10. The bandage as defined in claim 3 wherein said medicament comprises 0.1% to 15% by weight of povidone-iodine;

11. The bandage as defined in claim 3 wherein said medicament comprises 0.1% to 5% by weight of camphor;

12. The bandage as defined in claim 4 wherein said medicament comprises 0.1% to 5% by weight of camphor;






0072251

13. The bandage as defined in claim 3 wherein said medicament comprises 0.1% to 15% by weight of methyl salicylate;

14. The bandage as defined in claim 1 wherein said matrix has adhesive properties whereby the surface which contacts the skin defines said adhesive surface;

15. The bandage as defined in claim 1 wherein said backing element is a pressure-sensitive adhesive element and defines said adhesive surface which contacts the patient's skin.








Fig. 1




Fig. 2




Fig. 3



Fig. 4




Fig. 5

THIS PAGE BLANK (USPTO)